How Often to Check Vitamin B12 Before Giving Injection
You should check vitamin B12 levels once before initiating injectable therapy to confirm deficiency, then do not routinely recheck levels before subsequent injections during the initial treatment phase—treat based on clinical response instead.
Initial Testing Strategy
Before starting injectable B12 therapy, obtain a single baseline measurement using either:
- Total serum B12 (first-line test, most cost-effective at £2 per test) 1
- Active B12 (holotranscobalamin) if total B12 is indeterminate 1
Interpreting Your Initial Test
| Total B12 Level | Active B12 Level | Action |
|---|---|---|
| <180 ng/L (133 pmol/L) | <25 pmol/L | Confirmed deficiency—start treatment immediately [1] |
| 180-350 ng/L | 25-70 pmol/L | Consider methylmalonic acid (MMA) testing to confirm [1] |
| >350 ng/L | >70 pmol/L | Deficiency unlikely [1] |
Treatment Without Repeated Testing
Critical point: Once deficiency is confirmed and you initiate injectable therapy, you do not need to recheck B12 levels before each injection during the treatment course. The guidelines emphasize treating based on clinical response, not laboratory values 2.
Injectable Treatment Protocols
For patients WITH neurological involvement:
- Hydroxocobalamin 1 mg IM on alternate days until no further improvement
- Then 1 mg IM every 2 months for maintenance 2
For patients WITHOUT neurological involvement:
- Hydroxocobalamin 1 mg IM three times weekly for 2 weeks
- Then 1 mg IM every 2-3 months lifelong 2
When to Monitor After Treatment Initiation
The evidence suggests monitoring schedules for ongoing surveillance (not pre-injection checks):
- Post-bariatric surgery patients: Check B12 at 3,6, and 12 months in the first year, then at least annually 2
- Inflammatory bowel disease patients with ileal involvement: Screen yearly 3
- General at-risk populations: Every 2-3 years 4
Critical Pitfalls to Avoid
Never give folic acid before confirming and treating B12 deficiency—this can mask B12 deficiency and precipitate subacute combined degeneration of the spinal cord 2
Don't delay treatment for test results if neurological symptoms are present—start treatment immediately and seek urgent specialist advice 2
Don't stop injections prematurely based on normalized lab values—patients with malabsorption require lifelong maintenance therapy 2
Don't use serum B12 levels to guide dosing during active treatment—clinical improvement (resolution of neurological symptoms, normalization of blood counts) is the endpoint, not laboratory normalization 2
Special Considerations
For patients with confirmed malabsorption (pernicious anemia, post-gastrectomy, ileal resection >20-30 cm), prophylactic monthly injections are indicated indefinitely without the need for repeated testing to justify continuation 3.
The 2024 NICE guideline cost-effectiveness analysis supports testing MMA only when initial B12 results are indeterminate, not as routine monitoring during treatment 1.